Search results for "first episode psychosi"

showing 10 items of 49 documents

Jumping to conclusions, general intelligence, and psychosis liability: Findings from the multi-centre EU-GEI case-control study

2021

This study was funded by the Medical Research Council, the European Community’s Seventh Framework Program grant [agreement HEALTH-F2-2009-241909 (Project EU-GEI)], São Paulo Research Foundation (grant 2012/0417-0), the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London, the NIHR BRC at University College London and the Wellcome Trust (grant 101272/Z/12/Z).

MaleMISCOMPREHENSIONIntelligenceDELÍRIO0302 clinical medicineCognitionSCHIZOPHRENIApsychotic-like experiencejumping to conclusionsApplied PsychologyProblem SolvingRISKeducation.field_of_studyCognitionMiddle Aged16. Peace & justiceCognitive bias3. Good healthFirst episode psychosis; IQ; jumping to conclusions; polygenic risk score; psychotic-like experiences; symptom dimensionsPsychiatry and Mental healthBIASSchizophreniaRELIABILITYFemaleOriginal Articlejumping to conclusion[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]medicine.symptomClinical psychologyAdultPsychosisFirst episode psychosisAdolescentDISORDERSPopulationREEXAMINATIONDelusionssymptom dimensions03 medical and health sciencesYoung AdultPEOPLEmedicineHumansCognitive DysfunctioneducationDELUSIONAL IDEATIONCognitive deficitpsychotic-like experiencesbusiness.industryCase-control studymedicine.diseaseFirst episode psychosi030227 psychiatryPsychotic DisordersIQCase-Control StudiesJumping to conclusionspolygenic risk scorebusiness030217 neurology & neurosurgeryPsychological medicine
researchProduct

The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study.

2019

Background: Cannabis use is associated with increased risk of later psychotic disorder but whether it affects incidence of the disorder remains unclear. We aimed to identify patterns of cannabis use with the strongest effect on odds of psychotic disorder across Europe and explore whether differences in such patterns contribute to variations in the incidence rates of psychotic disorder. Methods: We included patients aged 18–64 years who presented to psychiatric services in 11 sites across Europe and Brazil with first-episode psychosis and recruited controls representative of the local populations. We applied adjusted logistic regression models to the data to estimate which patterns of canna…

MaleMarijuana Abusecannabis psychosis first episode psychosis incidenceENGLANDHIGH-POTENCY CANNABIS0302 clinical medicineSCHIZOPHRENIAOdds RatioMedicine030212 general & internal medicinepsychosisSalut mentalRISKeducation.field_of_studybiologyIncidence (epidemiology)IncidenceArticlesASSOCIATIONMiddle Aged3. Good healthEuropePsychiatry and Mental healthPUBLIC-HEALTHFemaleCase-Control StudieBrazilHumanAdultmedicine.medical_specialtyPsychosisPopulationPsychotic DisorderOdds03 medical and health sciencesYoung Adultfirst episode psychosisJournal ArticleHumanseducationSettore MED/25 - PsichiatriaBiological PsychiatryCannabisbusiness.industryLONDONPublic healthCase-control studyOdds ratiobiology.organism_classificationmedicine.diseaseTRENDS030227 psychiatryPsychotic DisordersMARIJUANACase-Control StudiesCannabisDroguesbusinessDemography
researchProduct

Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: Results from the EU-GEI case-control study

2021

The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) Project was funded by grant agreement Health-F2-2010-241909 (Project EU-GEI) from the European Community’s Seventh Framework programme. The Brazilian study was funded by grant 2012-0417-0 from the São Paulo Research Foundation. Dr Jongsma is funded by the Economic and Social Research Council (grant ES/S011714/1). Dr Kirkbride is funded by the Wellcome Trust and Royal Society (Grant 101272/Z/13/Z). Dr Jongsma and Professor Jones are funded by the National Institute of Health Research Collaboration of Leadership in Applied Health Research and Care East of England. Professor Rutten is funded…

MaleSocial Determinants of HealthEthnic groupPoison controlIMMIGRANTSOccupational safety and health0302 clinical medicinepsychotic disordersSCHIZOPHRENIADiscriminationOdds RatioApplied PsychologyRISKHYPOTHESISCommunication BarriersLinguistic distanceMiddle AgedDiscrimination; epidemiology; ethnicity; psychotic disorders; social disadvantage3. Good healthSocial researchEuropePsychiatry and Mental healthMIGRANT GROUPSethnicityFemaleepidemiologySTRIATAL DOPAMINE FUNCTIONAdultAdolescentDISORDERSsocial disadvantage1ST EPISODEBlack PeopleLibrary scienceTRANSTORNOS PSICÓTICOSWhite PeopleYoung Adult03 medical and health sciencesFirst episode psychosisPolitical scienceHumansMinority statusINCIDENCE RATESHealth Status DisparitiesOriginal Articlespsychotic disorder030227 psychiatryCase-Control StudiesEthnic and Racial MinoritiesIDENTITYGene-Environment InteractionSocial disadvantage030217 neurology & neurosurgery
researchProduct

Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: The EU-GEI case-control study

2021

The work was supported by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College Hospital NHS Foundation Trust to DQ; DFG Heisenberg professorship (no. 389624707) to UR. National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by t…

Marijuana AbuseIMPACTPoison controlCannabis usecannabis-associated psychosis0302 clinical medicineSCHIZOPHRENIASettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.health care economics and organizationsApplied PsychologyRISKOUTCOMESbiologyHuman factors and ergonomics/dk/atira/pure/subjectarea/asjc/2700/2738psychopathologyCannabis use; cannabis-associated psychosis; first episode psychosis; psychopathology; psychotic experiences; symptom dimensions3. Good healthPsychiatry and Mental healthSchizophreniaHEALTHPsychopathologyPsychosismedicine.medical_specialtyDISORDERSeducationsymptom dimensions03 medical and health sciencesInjury preventionfirst episode psychosismedicineHumanspsychotic experiencesPsychiatryABUSESettore MED/25 - PsichiatriaSUBSTANCE USEMETAANALYSISCannabisbusiness.industryCase-control studyOriginal Articlesmedicine.diseasebiology.organism_classification030227 psychiatrypsychotic experiencePsychotic Disordersfirst episode psychosiCase-Control StudiesONSETGene-Environment Interaction/dk/atira/pure/subjectarea/asjc/3200/3202Cannabisbusinesscannabis-associated psychosi030217 neurology & neurosurgery
researchProduct

Substance use, medication adherence and outcome one year following a first episode of psychosis

2016

Both substance use and poor medication adherence are associated with poor outcome in psychosis. To clarify the contributions of substance use and poor medication adherence to poor outcome in the year following a first episode of psychosis, 205 patients were evaluated for use of tobacco, alcohol, cannabis and stimulants at their psychosis onset, and in a 1-year follow-up. Data on medication adherence and symptom remission were also collected. Patients had high rates of overall substance use before (37-65%) and after psychosis onset (45-66%). 44% showed poor medication adherence and 55% did not reach remission from psychosis. Nicotine dependence and cannabis use after psychosis onset signific…

Nicotine dependenceAdultMalePsychosismedicine.medical_specialtyFirst episode psychosisRemissionSubstance-Related DisordersMedication adherenceSubstance useCannabis useMedication AdherenceCannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use; Acute Disease03 medical and health sciencesYoung Adult0302 clinical medicineSettore M-PSI/08 - Psicologia ClinicamedicineHumansYoung adultCannabis use; First episode psychosis; Medication adherence; Nicotine dependence; Remission; Substance use; Acute Disease; Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Psychotic Disorders; Substance-Related Disorders; Treatment Outcome; Young AdultNicotine dependencePsychiatryMedication adherenceSettore MED/25 - PsichiatriaBiological PsychiatryFirst episodebiologyCannabis useMiddle Agedmedicine.diseasebiology.organism_classificationFirst episode psychosi030227 psychiatryTreatment OutcomePsychotic DisordersPsychiatry and Mental HealthAcute DiseaseFemaleCannabisSubstance usePsychology030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up Studies
researchProduct

F115POLYGENIC RISK SCORES FOR SCHIZOPHRENIA, BIPOLAR, AND MAJOR DEPRESSIVE DISORDERS PREDICT TRANSDIAGNOSTIC SYMPTOM DIMENSIONS AT FIRST EPISODE PSYC…

2019

Background: The value of the nosological distinction between non-affective and affective psychosis has consistently been challenged. Indeed, psychotic syndromes are composed of dimensions of psychopathology cutting across diagnostic boundaries. Such transdiagnostic symptom dimensions might be enhanced phenotypes to test for association with common genetic variants for Major Mental Disorders (MMDs) as summarized by Polygenic Risk Scores (PRSs) for Schizophrenia (SZ), Bipolar Disorder (BP), and Major Depressive Disorder (MDD). The objectives of this study were to: 1) identify the symptom dimension structure at First Episode Psychosis (FEP); 2) examine the extent to which MMDs PRSs explain the…

Pharmacologymedicine.medical_specialtybusiness.industrypolygenic psychosis spectrum symptomsmedicine.diseasePsychiatry and Mental healthNeurologySchizophreniaFirst episode psychosismedicinePharmacology (medical)Neurology (clinical)businessPsychiatrySettore MED/25 - PsichiatriaBiological PsychiatryEuropean Neuropsychopharmacology
researchProduct

Cognitive Deficits in Patients with First-Episode Psychosis as Identified by Exner’s Schizophrenia Index in Finland and Spain

2002

Psychiatry and Mental healthClinical Psychologymedicine.medical_specialtyIndex (economics)SchizophreniaFirst episode psychosismedicineIn patientCognitionmedicine.diseasePsychiatryPsychologyRorschachiana
researchProduct

T52. COGNITION, METACOGNITION AND SOCIAL COGNITION AFTER A FIRST EPISODE PSYCHOSIS. PRELIMINARY RESULTS FROM A 5-YEAR-FOLLOW-UP STUDY

2020

Abstract Background Cognitive impairment is considered a core feature of psychotic disorders. Deficits in cognition, metacognition and social cognition have been reported to be correlated, and indeed predictors, of functional outcome or level of disability. Psychotic patients tend to present lower IQ and show impairment in specific cognitive domains, and in social cognition, than controls. Several studies have found deficits in facial emotion recognition (FER) and a higher prevalence of the jumping to conclusions (JTC) reasoning and data gathering biases among psychotic patients, even at time of illness onset, compared to controls. However, the trajectory of this impairment remains unclear.…

Psychiatry and Mental healthPoster Session III5 year follow upSocial cognitionAcademicSubjects/MED00810First episode psychosisMetacognitionCognitionPsychologyClinical psychologySchizophrenia Bulletin
researchProduct

S68. UNALTERED FRONTAL AND PREFRONTAL BRAIN RESPONSE DURING WORK MEMORY TASKS IN PATIENTS WITH A FIRST EPISODE PSYCHOSIS META-ANALYSIS STUDY

2019

BACKGROUND: There is extensive evidence that frontal and prefrontal cortex have abnormal functioning in patients with schizophrenia (Weinberger et al., 2001). For example, with functional magnetic resonance imaging (fMRI), multiple studies have shown altered activation during working memory tasks in these patients compared with controls (Adamczyk et al., 2017; Li et al., 2017). While most of the studies have been conducted in patients with chronic illness, whether these findings translate to individuals at the time of presenting with a First Episode Psychosis (FEP) is less well understood (Soldevila-Matias et al., 2018). The main objective of this study was to meta-analyze fMRI studies that…

Psychiatry and Mental healthPoster Session IIIbusiness.industryMeta-analysisFirst episode psychosisMedicineIn patientWork memorybusinessbehavioral disciplines and activitiesClinical psychology
researchProduct

S153. WHERE IS THE ABNORMAL BRAIN ACTIVITY IN FIRST EPISODE PSYCHOSIS?

2018

Abstract Background Recent review about functional magnetic resonance imaging (fMRI) in first episode psychosis (FEP) concluded that there is an abnormal connectivity involving the frontal temporal pathway similar to found in chronic schizophrenia (Mwansisya et al., 2017). Besides, thalamic circuits were also altered in chronic schizophrenia patients (Li et al., 2017). The present work gives a wider review of studies using functional magnetic resonance imaging techniques (fMRI) on first-episode psychotic patients, specifically focus on the main areas involved. Methods The review was made in accordance with the PRISMA guidelines (Moher et al., 2009). For each study, the following factors wer…

Psychiatry and Mental healthmedicine.medical_specialtyAbstractsPoster Session IIIText miningbusiness.industryBrain activity and meditationFirst episode psychosisMedicinebusinessPsychiatrySchizophrenia Bulletin
researchProduct